Intensity Therapeutics, Inc. Common stock Total Assets
Intensity Therapeutics, Inc. Common stock total assets. Based on the latest financial reports, Intensity Therapeutics, Inc. Common stock (INTS) holds total assets worth $12.29 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see INTS market cap for the company's overall valuation and market capitalisation.
Total Assets of Intensity Therapeutics, Inc. Common stock (2019–2025)
Total assets of Intensity Therapeutics, Inc. Common stock from 2019 to 2025. This chart illustrates how Intensity Therapeutics, Inc. Common stock's total assets have evolved over time, based on quarterly financial data. See INTS stock price and chart for real-time trading data and today's change.
Intensity Therapeutics, Inc. Common stock - Asset Composition Analysis
Intensity Therapeutics, Inc. Common stock Total Assets Breakdown (December 2025)
Intensity Therapeutics, Inc. Common stock total assets breakdown as of December 2025. Intensity Therapeutics, Inc. Common stock's total assets of $12.29 Million consist of 90.1% current assets and 9.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 84.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Intensity Therapeutics, Inc. Common stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of Intensity Therapeutics, Inc. Common stoc to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Intensity Therapeutics, Inc. Common stock's current assets represent 90.1% of total assets in 2025, a decrease from 96.0% in 2019.
- Cash Position: Cash and equivalents constituted 84.5% of total assets in 2025, up from 42.5% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Intensity Therapeutics, Inc. Common stock Competitors by Total Assets
Key competitors of Intensity Therapeutics, Inc. Common stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Intensity Therapeutics, Inc. Common stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.86 | 0.63 | 5.47 |
| Quick Ratio | 4.86 | 0.63 | 5.47 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $8.66 Million | $-978.00K | $6.75 Million |
Intensity Therapeutics, Inc. Common stock - Advanced Valuation Insights
This section examines the relationship between Intensity Therapeutics, Inc. Common stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.01 |
| Latest Market Cap to Assets Ratio | 0.65 |
| Asset Growth Rate (YoY) | 194.8% |
| Total Assets | $14.10 Million |
| Market Capitalization | $9.14 Million USD |
Valuation Analysis
Below Book Valuation: The market values Intensity Therapeutics, Inc. Common stock's assets below their book value (0.65x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Intensity Therapeutics, Inc. Common stock's assets grew by 194.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Intensity Therapeutics, Inc. Common stock (2019–2025)
The table below shows the annual total assets of Intensity Therapeutics, Inc. Common stock from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $14.10 Million | +194.81% |
| 2024-12-31 | $4.78 Million | -72.34% |
| 2023-12-31 | $17.30 Million | +884.35% |
| 2022-12-31 | $1.76 Million | -66.32% |
| 2021-12-31 | $5.22 Million | -48.61% |
| 2020-12-31 | $10.15 Million | +12.70% |
| 2019-12-31 | $9.01 Million | -- |
About Intensity Therapeutics, Inc. Common stock
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is… Read more